Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech (NASDAQ: ONCY) announced a conference call and webcast to discuss its fourth quarter and full year 2022 financial results, scheduled for March 3, 2023, at 8:30 a.m. ET. The call will cover corporate updates and financial insights regarding the company’s lead immunotherapeutic agent, pelareorep, which is in trials for treating various cancers. The company is advancing towards registration studies in metastatic breast cancer and pancreatic cancer while evaluating pelareorep in combination with immune checkpoint inhibitors.
- Advancing clinical trials for pelareorep in metastatic breast cancer and pancreatic cancer.
- Potential synergies with immune checkpoint inhibitors and other oncology treatments.
- None.
Conference call and webcast to take place on Friday, March 3, 2023, at 8:30 a.m. ET
SAN DIEGO and CALGARY, AB, Feb. 21, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 3, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2022.
Conference Call & Webcast
Date: Friday, March 3, 2023
Time: 8:30 a.m. ET
Dial In – North American Toll-Free: (888) 664-6383
Dial In – International: (416) 764-8650
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 4947-4770
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 474-770#.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards registration studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.
Company Contact Jon Patton Director of IR & Communication +1-858-886-7813 jpatton@oncolytics.ca | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 tim@lifesciadvisors.com |
Logo: https://mma.prnewswire.com/media/1808285/Oncolytics_Biotech_Grey.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-301750201.html
SOURCE Oncolytics Biotech® Inc.
FAQ
What is Oncolytics Biotech's upcoming conference call about?
When is Oncolytics Biotech's conference call scheduled?
What is the focus of Oncolytics Biotech's clinical trials?
How can I access Oncolytics Biotech's conference call?
